Skip to main content
Premium Trial:

Request an Annual Quote

FDA Issues Emergency Use Authorization for GenMark Coronavirus Assay

NEW YORK – The US Food and Drug Administration has issued Emergency Use Authorization for GenMark Diagnostics' ePlex SARS-CoV-2 Test, the firm announced Thursday evening.

The test qualitatively detects SARS-CoV-2 virus in nasopharyngeal swab samples and is for use on GenMark's sample-to-answer ePlex system, which is based on competitive DNA hybridization and electrochemical detection technology.

The company noted that the global installed base of the instrument stood at more than 500 as of the end of 2019 and added that the platform provides results in less than two hours and can process up to 96 tests per eight-hour shift.

During GenMark's fourth quarter earnings conference call earlier this month, it said that it had begun shipping its SARS-CoV-2 tests to its distributor in Hong Kong and to hospitals in the US, and that it would use information from customers using the test, which was then research use only, to apply to the FDA for EUA.

The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.